# Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography

> **NCT04338165** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Grenoble** · enrollment: 66 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Evolocumab 140 MG/ML [Repatha]

## Key facts

- **NCT ID:** NCT04338165
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-08
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338165, "Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04338165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*